We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.06B
1-Year Est. Return 215.32%
This Fund
S&P 500
This Quarter Est. Return
-12.58%
1 Year Est. Return
+215.32%
3 Year Est. Return
+310.3%
5 Year Est. Return
+497.45%
10 Year Est. Return
+14,692.23%
AUM
$3.2B
AUM Growth
+$58.8M
Cap. Flow
+$623M
Cap. Flow %
19.5%
Top 10 Hldgs %
58.78%
Holding
99
New
23
Increased
20
Reduced
15
Closed
12
Avg Time Held Equity + Options
3.5 quarters
Top 10 Avg Time Held Equity + Options
4.8 quarters
Top 20 Avg Time Held Equity + Options
5.1 quarters
Avg Time Held Equity only
3.5 quarters
Top 10 Avg Time Held Equity only
4.8 quarters
Top 20 Avg Time Held Equity only
5.1 quarters

Top Buys

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$158M
2
ZLAB icon
Zai Lab
ZLAB
+$107M
3
ARVN icon
Arvinas
ARVN
+$93.6M
4
ACAD icon
Acadia Pharmaceuticals
ACAD
+$70.9M
5
LKFT icon
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$59.4M

Top Sells

Rank Stock Value
1
CRSP icon
CRISPR Therapeutics
CRSP
+$81.7M
2
GRTS icon
Gritstone bio, Inc. Common Stock
GRTS
+$77.3M
3
RCUS icon
Arcus Biosciences
RCUS
+$75.7M
4
PTGX icon
Protagonist Therapeutics
PTGX
+$63.6M
5
ITOS icon
iTeos Therapeutics
ITOS
+$44.7M

Sector Composition

Rank Sector Weight
1 Healthcare 99.15%
2 Financials 0.61%
3 Miscellaneous 0.24%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
PRTA icon
1
Prothena Corp
PRTA
$423M
$424M 13.25%
11,584,280
+300,000
+3% +$10.8M
2018 Q4
13 quarters
APLS icon
2
DELISTED
Apellis Pharmaceuticals
APLS
$263M 8.24%
5,183,431
+1,149,549
+28% +$50.7M
2021 Q4
1 quarter
LKFT icon
3
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.87B
$198M 6.2%
3,195,624
+971,221
+44% +$59.4M
2021 Q3
2 quarters
ANAB icon
4
AnaptysBio
ANAB
$1.36B
$186M 5.82%
7,521,024
– –
2019 Q4
9 quarters
SRPT icon
5
Sarepta Therapeutics
SRPT
$1.75B
$162M 5.06%
+2,069,634
New +$158M
2022 Q1
0 quarters
MORF icon
6
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$159M 4.96%
3,951,566
– –
2019 Q2
11 quarters
ACAD icon
7
Acadia Pharmaceuticals
ACAD
$3.2B
$145M 4.54%
5,991,479
+2,930,886
+96% +$70.9M
2021 Q4
1 quarter
XNCR icon
8
Xencor
XNCR
$1.75B
$133M 4.15%
4,968,756
+62,650
+1% +$2.02M
2018 Q4
13 quarters
KURA icon
9
Kura Oncology
KURA
$868M
$107M 3.34%
6,638,371
+2,913,934
+78% +$42.1M
2015 Q4
25 quarters
RCUS icon
10
Arcus Biosciences
RCUS
$2.88B
$103M 3.22%
3,265,101
-2,258,257
-41% -$75.7M
2018 Q1
16 quarters
ARVN icon
11
Arvinas
ARVN
$446M
$101M 3.17%
1,503,929
+1,373,629
+1,054% +$93.6M
2021 Q4
1 quarter
ZLAB icon
12
Zai Lab
ZLAB
$2.49B
$97.8M 3.06%
+2,223,212
New +$107M
2022 Q1
0 quarters
ALEC icon
13
Alector
ALEC
$205M
$81.8M 2.56%
5,738,448
+743,478
+15% +$11.8M
2021 Q1
4 quarters
NUVB icon
14
Nuvation Bio
NUVB
$1.65B
$73.1M 2.29%
13,896,543
– –
2021 Q1
4 quarters
RLAY icon
15
Relay Therapeutics
RLAY
$3.75B
$68.6M 2.15%
2,291,441
+512,357
+29% +$12.4M
2020 Q3
6 quarters
RETA
16
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$64.7M 2.02%
+1,975,611
New +$58.6M
2022 Q1
0 quarters
TSVT icon
17
DELISTED
2seventy bio
TSVT
$59.6M 1.87%
3,495,943
+1,578,880
+82% +$26.8M
2021 Q4
1 quarter
CERE icon
18
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$57.6M 1.8%
+1,646,260
New +$48.1M
2022 Q1
0 quarters
RNAM
19
DELISTED
Avidity Biosciences
RNAM
$51M 1.59%
2,759,505
– –
2020 Q2
7 quarters
AVIR icon
20
Atea Pharmaceuticals
AVIR
$394M
$45.8M 1.43%
6,340,639
+964,505
+18% +$6.55M
2021 Q4
1 quarter
MRTX
21
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$41.2M 1.29%
+500,622
New +$51.2M
2022 Q1
0 quarters
ARGX icon
22
argenx
ARGX
$51B
$39.4M 1.23%
+125,000
New +$36.3M
2022 Q1
0 quarters
DSGN icon
23
Design Therapeutics
DSGN
$601M
$38.3M 1.2%
2,371,445
+218,448
+10% +$3.35M
2021 Q1
4 quarters
RVMD icon
24
Revolution Medicines
RVMD
$40.4B
$32.5M 1.02%
+1,274,097
New +$27.7M
2022 Q1
0 quarters
PCVX icon
25
Vaxcyte
PCVX
$10.5B
$31.5M 0.99%
1,304,741
+1,283,941
+6,173% +$28.1M
2021 Q4
1 quarter
1
2 3 4

Similar funds

RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
ST
Spinnaker Trust Portland, Maine $2.06B AUM 24.94% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return

EcoR1 Capital's Q1 2022 Portfolio in Review

As of Q1 2022, EcoR1 Capital held 99 positions worth $3.2B, up 1.9% from $3.14B the previous quarter. Its ten largest holdings account for 59% of the portfolio.

EcoR1 Capital deployed $623M of net new capital in Q1 2022, opening 23 new positions and adding to 20 existing holdings. Its largest new stake was Sarepta Therapeutics: 2,069,634 shares worth $162M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Financials and Miscellaneous.

On the sell side, the largest reduction was Arcus Biosciences, an estimated $75.7M trimmed.

  • EcoR1 Capital's largest Q1 2022 buy was Sarepta Therapeutics: 2,069,634 shares worth $162M.
  • EcoR1 Capital added most to Arvinas in Q1 2022, an estimated $93.6M increase.
  • EcoR1 Capital's biggest Q1 2022 reduction was Arcus Biosciences, cutting an estimated $75.7M.
  • EcoR1 Capital fully exited CRISPR Therapeutics in Q1 2022, selling an estimated $81.7M.
  • EcoR1 Capital's ten largest holdings make up 59% of its $3.2B portfolio in Q1 2022.
  • EcoR1 Capital opened 23 new positions and closed 12 in Q1 2022.
  • EcoR1 Capital's portfolio value rose 1.9% quarter-over-quarter to $3.2B.

Based on EcoR1 Capital's 13F filing for Q1 2022, filed 16 May 2022.